中期因子蛋白在脑胶质瘤中的表达及其临床意义

Expression of Midkine in Human Glioma and Its Significance

目的:研究人脑胶质瘤中中期因子蛋白(MK)和增殖细胞核抗原(PCNA)的表达,探讨两者在胶质瘤的侵袭和恶性进展中的作用。方法:应用免疫组化SP法检测48例脑胶质瘤和10例正常脑组织中MK和PCNA的表达和分布情况。结果:MK和PCNA在正常脑组织中均无表达。在48例脑胶质瘤中39例有MK的表达,其在高级别脑胶质瘤中的阳性表达率明显高于低级别脑胶质瘤的阳性表达率(P<0.01)。PCNA在41例胶质瘤中表达,其在高级别胶质瘤中的表达明显高于低级别胶质瘤(P<0.01)。并且发现MK和PCNA在人脑胶质瘤中的表达呈正相关(r=0.635,P<0.01)。MK的阳性表达患者生存时间明显低于阴性患者,两者间差异有明显统计学意义。结论:MK在脑胶质瘤中的高表达与肿瘤的发生发展和细胞增殖有关,可以作为一个反映脑胶质瘤增殖能力和恶性程度的指标,为胶质瘤的基因治疗提供一个新的靶点。

Objective： To explore the expression of midkine and PCNA in human cerebral gliomas and their effects on the invasion and malignant development of human cerebral glioma. Methods： The expression and distribution of midkine and PCNA were determined by immunohistochemical technique （SP method） in 48 cases of human cerebral gliomas and 10 cases of normal brain tissues. Results： The midkine expression in 39 cases of gliomas was positive. The positive expression rate of midkine in the high grade gliomas was significantly higher than that in the low grade ones （P〈 0.01）. The expression of PCNA was observed in 41 cases of the glioma. The expression of midkine and PCNA was significantly higher in the high grade gliomas than in the low grade ones respectively （both P〈0.01）. The expression of midkine was positively related to that of PCNA in human cerebral gliomas （r=0. 635, P〈0.01）. The survival time of patients with midkine positive expression was significantly lower than that of negative patients with significant difference. Conclusion. The high expression of midkine in the glioma has some relationship to tumor cell proliferation and development. It can be used as a marker for malignance and proliferation of glioma, and provides a new target for the gene therapy.